These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38134746)

  • 21. MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.
    Yamamoto M; Jin C; Hata T; Yasumizu Y; Zhang Y; Hong D; Maeda T; Miyo M; Hiraki M; Suzuki Y; Hinohara K; Rajabi H; Kufe D
    Cancer Res; 2019 Apr; 79(8):2031-2041. PubMed ID: 30824588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis, and biological evaluation of quinazolin-4(3
    Chang X; Sun D; Shi D; Wang G; Chen Y; Zhang K; Tan H; Liu J; Liu B; Ouyang L
    Acta Pharm Sin B; 2021 Jan; 11(1):156-180. PubMed ID: 33532187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
    Song D; He H; Sinha I; Hases L; Yan F; Archer A; Haldosen LA; Zhao C; Williams C
    Cancer Lett; 2021 May; 506():23-34. PubMed ID: 33652085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
    Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
    Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
    Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A
    PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.
    Pu C; Tong Y; Liu Y; Lan S; Wang S; Yan G; Zhang H; Luo D; Ma X; Yu S; Huang Q; Deng R; Li R
    Eur J Med Chem; 2022 Jun; 236():114321. PubMed ID: 35430559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
    Chen W; Guo N; Qi M; Dai H; Hong M; Guan L; Huan X; Song S; He J; Wang Y; Xi Y; Yang X; Shen Y; Su Y; Sun Y; Gao Y; Chen Y; Ding J; Tang Y; Ren G; Miao Z; Li J
    Eur J Med Chem; 2017 Sep; 138():514-531. PubMed ID: 28692916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    Jain PG; Patel BD
    Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers.
    Lin S; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Wu L
    Bioorg Med Chem; 2022 May; 61():116739. PubMed ID: 35393219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy.
    Chang CH; Bijian K; Wernic D; Su J; da Silva SD; Yu H; Qiu D; Asslan M; Alaoui-Jamali MA
    Autophagy; 2019 Aug; 15(8):1376-1390. PubMed ID: 30773992
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and biological evaluation of a tumor-selective degrader of PARP1.
    Pu C; Wang S; Luo D; Liu Y; Ma X; Zhang H; Yu S; Lan S; Huang Q; Deng R; He X; Li R
    Bioorg Med Chem; 2022 Sep; 69():116908. PubMed ID: 35780655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer.
    Wu Y; Wu M; Zheng X; Yu H; Mao X; Jin Y; Wang Y; Pang A; Zhang J; Zeng S; Xu T; Chen Y; Zhang B; Lin N; Dai H; Wang Y; Yao X; Dong X; Huang W; Che J
    Bioorg Chem; 2024 Jan; 142():106952. PubMed ID: 37952486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-silico method for elucidation of prodigiosin as PARP-1 inhibitor a prime target of Triple-negative breast cancer.
    Sundararajan P; Dharmaraj Rajaselvi D; Vivekananthan S; Priya Ramasamy S
    Bioorg Chem; 2023 Sep; 138():106618. PubMed ID: 37244231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cancer-testis gene,
    Gu Y; Wang C; Zhu R; Yang J; Yuan W; Zhu Y; Zhou Y; Qin N; Shen H; Ma H; Wang H; Liu X; Hu Z
    Cancer Biol Med; 2021 Feb; 18(1):74-87. PubMed ID: 33628586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
    Turk AA; Wisinski KB
    Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dual-target platinum(IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly(ADP-ribose) polymerase (PARP-1) and enhancing DNA damage.
    Li R; Zhao W; Jin C; Xiong H
    Bioorg Chem; 2023 Apr; 133():106354. PubMed ID: 36720184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells.
    Zeng X; Jiang S; Ruan S; Guo Z; Guo J; Liu M; Ye C; Dong J
    Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34080025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma
    Ali R; Al-Kawaz A; Toss MS; Green AR; Miligy IM; Mesquita KA; Seedhouse C; Mirza S; Band V; Rakha EA; Madhusudan S
    Cancer Res; 2018 Dec; 78(24):6818-6827. PubMed ID: 30297533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer.
    Gao G; Li J; Cao Y; Li X; Qian Y; Wang X; Li M; Qiu Y; Wu T; Wang L; Fang M
    Eur J Med Chem; 2023 Dec; 261():115858. PubMed ID: 37837671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.